CAMBRIDGE, Mass., March 27, 2018 – rHEALTH LLC announces the issuance of a new patent in the United States for instrument industrial design filed by DNA Medicine Institute, DMI. The design contributes to the diverse measurement capabilities of the rHEALTH digital health platform, which represents broad innovations in testing technologies.
The U.S. Patent and Trademark Office has granted the patent number D814,042, “Vital sign instrument,” for an integrated vital sign monitoring system for non-invasive, wireless, and continuous use. This new design patent highlights the companies’ expanding intellectual property portfolio, demonstrating DMI and rHEALTH’s ongoing commitment to bring better care through innovation in portable diagnostics and monitoring technologies.
rHEALTH is an innovative digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample intended as a point-of-care solution, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.